Protea introduces new molecular imaging technology

MORGANTOWN, W.Va., June 21, 2017 /PRNewswire/ -- Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") announced its development of new technology that enables the direct molecular imaging of the distribution of metabolites and peptides in human clinical tissue samples. The results were presented by Dr. Erin Seeley, Principal Scientist at Protea, at the 65th Annual Meeting of the American Society for Mass Spectrometry and Allied Topics, June 4-8, held in Indianapolis, Indiana.

Press Archive